Objective To define headache characteristics and evolution in relation to COVID-19 and its
inflammatory response. Methods This is a prospective study, comparing clinical data and …

Background In daily practice, anti-CGRP monoclonal antibodies (MAbs) may be useful in
chronic migraine (CM) with medication overuse (MO), but data is limited. We evaluated their …

… Marta Torres-Ferrus has received honoraria as a consultant or speaker for Allergan-Abbvie,
Almirall, Chiesi, Eli Lilly, Novartis and Teva. Alpuente A has received honoraria from …

Objective We aimed (1) to analyze salivary calcitonin gene‐related peptide (CGRP) levels in
patients with migraine, (2) to predict erenumab response from baseline CGRP levels, and (3…

Background and purpose The response pattern to monoclonal antibodies against calcitonin
gene‐related peptide (anti‐CGRP MAbs) shown in migraine prevention clinical trials is not …

One year after the outbreak of coronavirus disease 2019 (COVID‐19), referrals for persistent
headache, often defined as “post‐COVID headache,” have become increasingly common in …

Background There is a need to establish which are the more relevant headache-related
outcomes that have an impact on our patient’s lives to accurately evaluate treatment response in …

… Torres-Ferrus M has received honoraria as a consultant or speaker for Allergan-Abbvie,
Almirall, Chiesi, Eli Lilly, Novartis and Teva. Pareto D has received speaking honoraria from …

Background CGRP plays a key role in the transmission and modulation of nociceptive signals
and is a critical component in the pathogenesis of migraine. Objective To assess saliva as …

Objective To evaluate the prevalence and characteristics of headache and its relationship
with comorbidities and lifestyle in a teenage population. Methods This is a cross-sectional …